SAN DIEGO, March 2, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced the
completion of patient enrollment in the Company's Phase II
extension study of its investigational product ImmunoPulse™ IL-12
for the treatment of advanced melanoma. The trial's objective is to
evaluate an alternate dosing frequency and additional biomarkers to
provide further scientific understanding of ImmunoPulse™ IL-12 in
an extension of the OMS-I100 Phase II melanoma trial. The Company
expects to report consolidated data from the OMS-I100 and extension
studies by Q3 2016.
"We are committed to improving the lives of patients with
advanced melanoma and are pleased to have completed enrollment in
this Phase II study," said Punit
Dhillon, President and CEO of OncoSec. "Completing
enrollment in this study is an important step in the development
for ImmunoPulse™ IL-12 as it allows us to build upon our positive
Phase I and II results and inform our ongoing and future trials.
There is a significant opportunity to bring forward a new
generation of intratumoral immunotherapies for patients with
melanoma who typically don't respond to first-line immunotherapies
due to a low-TIL (tumor-infiltrating lymphocyte) phenotype. Our
intention is to use the results from this study along with data
from our OMS-I100 Phase II trial to formulate a combination
registration path for ImmunoPulse™ IL-12 in melanoma."
The objective of the extension study is to assess the safety and
efficacy of a six-week treatment cycle with ImmunoPulse™ IL-12 in
21 patients with advanced melanoma. The protocol extension provides
an opportunity to assess whether more frequent treatment with
ImmunoPulse™ IL-12 can provide additional clinical benefit to
patients. The details of the trial can be found at
www.clinicaltrials.gov.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "expect," "may," "will," "goal,"
"intention," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-completes-patient-enrollment-in-phase-ii-extension-study-of-immunopulse-il-12-in-melanoma-300229244.html
SOURCE OncoSec Medical Incorporated